Jorg Dietrich, M.D.,Ph.D.
This page shows the publications co-authored by Jorg Dietrich and Brian Nahed.
Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma. Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa031.
Bone marrow response as a potential biomarker of outcomes in glioblastoma patients. J Neurosurg. 2017 Jul; 127(1):132-138.
Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide. J Neurooncol. 2016 May; 127(3):505-14.
Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. Nat Commun. 2021 10 12; 12(1):5954.
A rapid genotyping panel for detection of primary central nervous system lymphoma. Blood. 2021 Aug 05; 138(5):382-386.
Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of chemotherapeutic management and antiangiogenic treatment of newly diagnosed glioblastoma in adults. J Neurooncol. 2020 Nov; 150(2):165-213.
Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med. 2020 Aug; 26(8):1309.
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med. 2020 08; 26(8):1280-1284.
Remote acute demyelination after focal proton radiation therapy for optic nerve meningioma. J Clin Neurosci. 2015 Aug; 22(8):1367-9.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.